The most common reason people visit their doctor, according to a study from the Mayo Clinic, may surprise you.
The FDA approves Bristol-Myers Squibb's Opdivo, pitting it against Merck's Keytruda that was approved earlier this year.
Pfizer is a staple in most retirement and income portfolios, but investors can find stronger growth prospects in each of these three big pharmaceutical stocks.
A recent study shows that while Obamacare has dramatically reduced the number of uninsured, it's failing to provide a boost in this important area which is vital to Obamacare's long-term success.
Sales of Bristol-Myers Squibb and Pfizer's Eliquis could grow if Portola Pharmaceuticals' andexanet alfa eventually gets FDA approval.
The FDA rejected daclatasvir, but Bristol-Myers Squibb still has plans for the hepatitis C drug.
We asked three of our top healthcare analysts which big pharma stocks could face tough times in 2015. Here is what they had to say.
Bristol-Myers Squibb is battling patent expiration, but some fast-growing new drugs just may be able to save its dividend.
Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.
Bristol-Myers Squibb was among the best performing pharmaceutical stocks in October, launching 15% higher and tacking on more than $12 billion in market value. Find out what sent Bristol-Myers' shares soaring higher and whether or not it'll continue.